Nov 5, 6:03 AM ET
Haemonetics reported second-quarter fiscal 2027 revenue of $357.8 million, up 9.3%, and GAAP earnings of $1.00 per diluted share, up from $0.81 a year earlier. The company raised its reported revenue growth guidance to 8% to 11% but narrowed its adjusted operating margin expansion guidance to 0 to 50 basis points from 50 to 100 basis points.
- Q2 revenue $357.8 million, up 9.3%; organic revenue growth 10.0%
- GAAP EPS $1.00 vs. $0.81 a year earlier; adjusted EPS $1.35, up 6.3%
- Reported revenue guidance raised to 8% to 11% from 5% to 8%; adjusted operating margin expansion lowered to 0 to 50 basis points from 50 to 100
- Q2 operating cash flow $128.1 million; free cash flow $103.8 million
Read the filing on SEC.gov ↗
Aug 6, 6:07 AM ET
Haemonetics reported first-quarter fiscal 2027 revenue of $339.4 million, up 5.6%, with GAAP earnings of $0.72 per diluted share versus $0.70 a year earlier. The company raised its fiscal 2027 organic revenue growth guidance to 4% to 7% from 3% to 6%, though GAAP net income fell 3.0% to $33.0 million.
- Q1 fiscal 2027 revenue was $339.4 million, up 5.6%; organic revenue growth was 5.9%.
- GAAP diluted EPS was $0.72 versus $0.70; adjusted diluted EPS was $1.14, up 3.6%.
- Organic revenue growth guidance was raised to 4% to 7% from 3% to 6%; reported revenue guidance was raised to 5% to 8% from 4% to 7%.
- Free cash flow was $39.1 million, up $36.6 million; cash on hand was $223.4 million as of June 27, 2026.
Read the filing on SEC.gov ↗
Jul 28, 4:28 PM ET
Haemonetics' board elected Martin Madaus, a Carlyle Group Senior Operating Executive, as a director effective July 24, 2026. At the same meeting, shareholders re-elected eight directors, approved an advisory say-on-pay vote, ratified Ernst & Young LLP as auditor, and approved amended 2019 Long-Term Incentive Compensation and 2007 Employee Stock Purchase Plans. The plan changes authorize 4,680,000 additional shares under the incentive plan and extend both plans through 2036.
- Martin Madaus elected director effective July 24, 2026; expected to join the Audit Committee and Governance and Compliance Committee
- Non-employee director annual equity award with an approximate value of $200,000
- Shareholders approved the incentive plan amendment, which authorizes 4,680,000 additional shares, with 37,730,923 votes for and 2,055,726 against
- Ellen Zane, Christopher Simon and six other nominees re-elected for one-year terms expiring in 2027
Read the filing on SEC.gov ↗
May 7, 6:02 AM ET
Haemonetics reported fourth-quarter fiscal 2026 revenue of $346.4 million, up 4.8%, and adjusted earnings of $1.29 per diluted share, up 4.0%. A $77.2 million impairment of intangible assets tied to Attune Medical turned the quarter to a GAAP net loss of $20.1 million, or $(0.44) per share, and the company also issued fiscal 2027 guidance calling for reported revenue growth of 4% to 7%.
- Q4 fiscal 2026 revenue of $346.4 million, up 4.8%; organic growth 4.5%, organic ex-CSL growth 8.6%
- Q4 GAAP net loss of $20.1 million, or $(0.44) per share, versus net income of $58.0 million, or $1.17 per share, a year earlier
- Fiscal 2026 revenue of $1.334 billion, down 2.0%; GAAP EPS $2.05 versus $3.31; adjusted EPS $4.96
- Fiscal 2027 guidance: reported revenue growth 4% to 7%, organic growth 3% to 6%, adjusted operating margin expansion of 50 to 100 basis points
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
